Sichenzia Ross Friedman Ference LLP Advises Sorrento Therapeutics, Inc. on $25.0 million Public Offering of Common Stock
NEW YORK, May 20, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Sorrento Therapeutics, Inc. (NASDAQ: SRNE), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, in a $25.0 million public offering. The offering consists of 4,765,000 shares of common stock priced at $5.25 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Jeff Fessler and Marcelle Balcombe.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Represents Marathon Patent Group, Inc. in $2.66 Million Registered Direct Offering. - April 24, 2017
- Sichenzia Ross Ference Kesner LLP Represents Laidlaw & Company (UK) Ltd. as Placement Agent for $2.1 Million Private Placement - April 16, 2017
- Ronen Kantor - April 11, 2017